C800 group was significantly better than that in the C400 group among patients infected with clarithromycin-sensitive strains (p = 0.03). This difference could be attributed to differences among smokers versus non-smokers: the cure rate among smokers in the C800 group (91.0%) was better than that in the C400 group (80.0%, p = 0.003). Conclusions: 800 mg of clarithromycin is recommended in the PPI/AC regimen for patients who smoke and are infected with clarithromycin-sensitive H. pylori .
Introduction
Eradication of Helicobacter pylori results in the healing of chronic active gastritis and reduces peptic ulcer recurrence [1, 2] . In addition, eradication of H. pylori improves pre-existing reflux esophagitis in duodenal ulcer patients [3] and also may reduce their risk of developing gastric cancer in patients after endoscopic resection of early gastric cancer [4] as well as in patients who have gastric ulcers [5, 6] . To eradicate H. pylori , a proton pump inhibitor (PPI) together with amoxicillin and clarithromycin (PPI/ Ishioka /Mizuno /Take /Ishiki /Nagahara / Yoshida /Okada /Yokota /Oguma Digestion 2007;75: [63] [64] [65] [66] [67] [68] 64 AC regimen, the so-called triple therapy) has been used as a standard first-line regimen [7] . Among factors influencing the effectiveness of the PPI/AC regimen, resistance of H. pylori to clarithromycin is a major reason for treatment failure [8, 9] . Genetic polymorphism of cytochrome P 2C19 (S-mephenytoin 4 -hydroxylase) also is believed to affect therapy, but results in this regard have been conflicting [9] [10] [11] [12] .
The effect of smoking is another controversial issue [13] [14] [15] [16] [17] . A recent study suggests that interactions between genetic polymorphism of cytochrome P 2C19 and smoking may influence the efficacy of the PPI/AC regimen [18] . Poor compliance [19] and pretreatment with PPI [20] or H 2 -receptor antagonist [14] have also been shown to be associated with eradication failure.
With regard to the clarithromycin dosage, a regimen with 1,000 mg of clarithromycin reportedly provides a better cure rate than that with 500 mg in Western countries [21] . In Japan, however, no significant difference has been found in the cure rate between clarithromycin 400 and 800 mg regimens [22, 23] . In the present study, we retrospectively compared the efficacy of 400 and 800 mg of clarithromycin used in the PPI/AC regimen in our Japanese patients with peptic ulcer disease. . 308 patients had gastric ulcer, 230 had duodenal ulcer, and 63 had both. The patients in this study include 83 patients in our previous study in which we examined the impact of IL-1 ␤ and cytochrome P 2C19 genetic polymorphism on the cure rate of the PPI/AC regimen [9] . A physical examination, blood chemistry, complete blood count, and urinalysis were performed, and a standard questionnaire was used to document any concurrent medical problems, smoking habits, alcohol consumption, drug allergy, and drug usage preceding the study.
Patients and Methods

Patients
H. pylori infection was defined as a positive bacterial culture from endoscopic biopsy specimens taken before eradication therapy was begun [3, 5, 9] . The susceptibilities of cultured H. pylori to amoxicillin and clarithromycin were assessed by use of E-test (AB Biodisk, Sweden). The cut-off concentrations used to define antibiotic resistance were 1 0.5 mg/ml for amoxicillin, and 1 1.0 mg/ml for clarithromycin [24] .
One to two months after the end of the eradication therapy, including the cessation of maintenance therapy with acid secretion inhibitors, a 13 C-urea breath test ( 13 C-UBT) and a follow-up endoscopy were performed to determine H. pylori status. Biopsy specimens were again obtained and cultured, and their urease activities and the susceptibilities of cultured H. pylori to amoxicillin and clarithromycin assessed as at entry. H. pylori infection was considered cured when the bacterial culture, rapid urease test, and 13 C-UBT were all negative (values lower than 3.5‰ for the 13 C-UBT [25] ). The study was conducted according to the guidelines of the Declaration of Helsinki. The local ethics committee approved the study protocol.
Statistical Analysis
Statistical differences in demographics and cure rates between the treatment groups were tested by use of Mann-Whitney U test, the 2 test and the Fisher's exact test. Factors associated with treatment failure were assessed by logistic regression analysis. p values were two-sided; values ! 0.05 were considered to be statistically significant.
Results
Clinical details of the patients are given in table 1 . 305 patients were treated with a regimen containing 400 mg of clarithromycin (C400 group), and 296 patients were treated with an 800 mg regimen (C800 group). There was no significant demographic difference between the treatment groups. With regard to resistance of H. pylori to antibiotics, no pretreatment resistance to amoxicillin was noted, whereas 40 of 601 patients (6.7%) were infected with clarithromycin-resistant strains ( table 1 ) .
In overall cure rates, a trend towards a better cure rate in the C800 group (259/296, 87.5%) than that in the GU/DU/GU+DU = Gastric ulcer/duodenal ulcer/gastric ulcer and duodenal ulcer; C400 = lansoprazole, amoxicillin and clarithromycin 400 mg/day group; C800 = lansoprazole, amoxicillin and clarithromycin 800 mg/day group.
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Digestion 2007;75: [63] [64] [65] [66] [67] [68] C400 group (250/305, 82%) was noted (p = 0.07). By logistic regression analysis, susceptibility to clarithromycin, dose of clarithromycin and smoking habits were identified as significant factors associated with treatment failure by univariate as well as by multivariate analyses ( table 2 ) .
A significantly better cure rate was noted among patients infected with clarithromycin-sensitive strains than among patients infected with resistant strains in both the C400 and C800 groups (p ! 0.0001, table 3 ). Among patients who had clarithromycin-resistant bacteria, there was no significant difference in the cure rate between the C400 (40.0%) and C800 (35.0%) groups. In contrast, the cure rate in the C800 group (91.3%) was significantly better than in the C400 group (84.9%) among patients who were infected with clarithromycin-sensitive strains (p = 0.03, table 3 ).
In the patients infected with clarithromycin-sensitive strains, a significantly better cure rate was noted among smokers in the C800 group (91.0%) when compared with C400 group smokers (80.0%, p = 0.003, table 4 ). In contrast, there was no difference in cure rates among nonsmokers in the C400 (94.1%) and the C800 (92.0%) groups. Among patients infected with clarithromycin-resistant strains, there was no significant difference between the C400 and C800 groups regardless of smoking ( table 4 ) . Thus, the trend towards a better cure rate in the C800 group was likely due to the better cure rate in smokers infected with clarithromycin-sensitive strains. There was no significant difference in compliance between smokers (98.6%) and non-smokers (99.0%). Cure rates (%) are given, with 95% confidence interval in parentheses. Number cured/total number in brackets. C400 = Lansoprazole, amoxicillin and clarithromycin 400 mg/day group; C800 = lansoprazole, amoxicillin and clarithromycin 800 mg/day group.
Ishioka /Mizuno /Take /Ishiki /Nagahara / Yoshida /Okada /Yokota /Oguma Adverse events were reported in 221 (36.8%) of the 601 patients. Four patients discontinued the treatment because of adverse events. Diarrhea or soft stool and loss of taste were the most common adverse events; loss of taste was more often seen in the C800 group than in the C400 group (p = 0.01). In total, there was no significant difference in the rate of adverse events between the C400 and C800 groups.
Discussion
In the present study, we compared the efficacy of PPI/ AC regimens containing 400 and 800 mg of clarithromycin in the H. pylori eradication therapy in the patients who have peptic ulcer disease. We found that the regimen containing 800 mg of clarithromycin provided a significantly better cure rate than a regimen containing 400 mg of clarithromycin in cigarette smokers who were infected with clarithromycin-sensitive strains. For clarithromycin-resistant strains, increasing the dose of clarithromycin did not improve the cure rate.
Several studies have shown that smoking is a factor associated with treatment failure in H. pylori eradication therapy [14, 15, 17, 18] . In our previous study [16] , smoking was a significant predictor for treatment failure in the 2-week dual therapy using PPI and amoxicillin. In our subsequent study using the PPI/AC regimen with clarithromycin 400 mg [9] , the cure rate was lower in smokers than that in non-smokers, but the difference did not reach the statistical significance. In the present study, by including more patients, we found a significantly negative impact of smoking on the efficacy of the PPI/AC regimen with clarithromycin 400 mg. In addition, we showed that the effect of smoking could be overcome by increasing the dose of clarithromycin among patients who were infected with clarithromycin-sensitive strains.
Many factors may contribute to the unfavorable effect of smoking on H. pylori eradication therapy. Smoking might have led to poor compliance, which is a factor associated with treatment failure [19] , but there was no significant difference in compliance between smokers and non-smokers in our study. Smoking stimulates acid secretion [26] , which is an obstacle to the efficacy of antibiotics in the stomach [27] . However, increasing the dose of PPI was shown not to improve eradication rate [28] . Instead, our present study showed that simply increasing the dose of clarithromycin is effective in improving the cure rate in smokers infected with clarithromycin-sensitive H. pylori . Smoking decreases gastric mucosal blood flow [29] , which may reduce the delivery of antibiotics to the gastric mucosa. Our findings support that local concentrations of the effective antibiotic delivered by gastric blood flow is important for eradication of H. pylori and suggest that the deficit of the antibiotic at gastric mucosa due to smoking can be restored by increasing the dose of clarithromycin.
Among factors influencing the effectiveness of the PPI/AC regimen, resistance of H. pylori to clarithromycin is a major reason for treatment failure [8, 9, 30] , as we confirmed in the present study. In the present study, raising dose of clarithromycin did not improve the cure rate in patients infected with clarithromycin-resistant strains. Resistance to clarithromycin in clinical H. pylori isolates is caused predominantly by distinct point mutations in 23S ribosomal RNA where clarithromycin binds [31] . It is apparent that increasing the clarithromycin dose not improve the cure rate when the H. pylori is resistant to this antibiotic, and the use of other antibiotics such as metronidazole should be considered in this situation.
A possible increase of adverse events was another concern when the dose of antibiotics was increased. Indeed, loss of taste was more often observed in the C800 than in the C400 group, but the overall rate of adverse events was not significantly different between the two groups. We conclude that 800 mg of clarithromycin is preferable in Cure rates (%) are given, with 95% confidence interval in parentheses. Number cured/total number in brackets. C400 = Lansoprazole, amoxicillin and clarithromycin 400 mg/day group; C800 = lansoprazole, amoxicillin and clarithromycin 800 mg/day group.
* p = 0.003 (C400 vs. C800); ** p = 0.002 (smoker vs. nonsmoker).
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Digestion 2007;75: [63] [64] [65] [66] [67] [68] PPI/AC eradication regimens for patients who smoke and are infected with clarithromycin-sensitive H. pylori . There is no apparent merit in increasing the dose of clarithromycin for either non-smoking patients or patients who are infected with clarithromycin-resistant strains.
